Results 71 to 80 of about 93,898 (384)

Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis [PDF]

, 2020
Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
Foerster, John, Molęda, Aleksandra
core   +2 more sources

Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma

Clinical Respiratory Journal, 2022
Patients with severe eosinophilic asthma experience daily activity limitations and reduced productivity at work. Using anonymized individual patient‐level data from two previously conducted randomized, double‐blind, placebo‐controlled studies (MENSA [GSK
F. Albers, D. Bratton, N. Gunsoy, S. Cockle, R. Alfonso-Cristancho, G. Braunstahl   +5 more
semanticscholar   +1 more source

Organization, Clinical and Management Indicators on the First Year of Activity of an Outpatient Clinic Dedicated to the Diagnosis and Treatment of Severe Asthma in Italy

Journal of Asthma and Allergy, 2021
Silvia Tognella,1 Claudio Micheletto,2 Alessandro Roggeri,3 Guido Polese,4 Denise Artioli,1 Gianenrico Senna,5 Marco Caminati,5,6 Daniela Paola Roggeri3 1Pulmonology Unit, Mater Salutis Hospital, Legnago (Verona), Italy; 2Pulmonology Unit, Azienda ...
Tognella S, Micheletto C, Roggeri A, Polese G, Artioli D, Senna G, Caminati M, Roggeri DP   +7 more
doaj  

Diagnosis and management of eosinophilic asthma: a US perspective. [PDF]

, 2014
Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and ...
Doherty, Taylor A, Walford, Hannah H
core   +1 more source

Assessing the Anti-Inflammatory Effects of an Orally Dosed Enzymatically Liberated Fish Oil in a House Dust Model of Allergic Asthma

Biomedicines, 2022
Eosinophils are a major driver of inflammation in a number of human diseases, including asthma. Biologic therapies targeting IL-5 have enabled better control of severe eosinophilic asthma, but no such advances have been made for enhancing the control of ...
Crawford Currie, Bomi Framroze, Dave Singh, Simon Lea, Christian Bjerknes, Erland Hermansen   +5 more
doaj   +1 more source

Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis

Respirology (Carlton South. Print)
Several randomized controlled trials (RCTs) have shown that benralizumab is characterized by a good profile of efficacy and safety, thereby being potentially able to elicit clinical remission on‐treatment of severe eosinophilic asthma (SEA).
C. Pelaia, C. Crimi, A. Benfante, M. Caiaffa, R. Campisi, Claudio Candia, G. E. Carpagnano, Isabella Carrieri, Maria D'Amato, Aikaterini Detoraki, M. P. F. Barbaro, N. Lombardo, L. Macchia, A. Maglio, Elena Minenna, S. Nolasco, Giuseppe Paglino, F. Papia, Luisa Ricciardi, Nicola Scichilone, Giulia Scioscia, G. Spadaro, Pasquale Tondo, Simona Uletta Lionetti, G. Valenti, A. Vatrella, N. Crimi, G. Pelaia   +27 more
semanticscholar   +1 more source

Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data

Journal of Asthma and Allergy, 2022
Background Reslizumab is an anti-interleukin 5 monoclonal antibody that has demonstrated to reduce the risk of severe exacerbations and to improve symptoms, lung function, and quality of life in randomized controlled trials that included patients with ...
L. A. Pérez de Llano, B. Cosío, I. Lobato Astiárraga, G. Soto Campos, M. A. Tejedor Alonso, N. Marina Malanda, A. Padilla Galo, I. Urrutia Landa, F. J. Michel de la Rosa, I. García-Moguel   +9 more
semanticscholar   +1 more source

A new formulation of oral viscous budesonide in treating of paediatric eosinophilic oesophagitis: a pilot study [PDF]

, 2017
OBJECTIVES: Oral viscous budesonide is a recent therapeutic option for eosinophilic oesophagitis (EoE) compared with dietary restriction and inhaled steroids.
Amil, D. J., Cucchiara, S., Isoldi, S., Lucarelli, S., Oliva, S., Papoff, P., Rossetti, D., Rossi, P., Tiberti, A.   +8 more
core   +1 more source

CD207‐Positive Dendritic Cells Promote Emphysema Through CD8+ T Cell Pathway in Chronic Obstructive Pulmonary Disease

Advanced Science, EarlyView.
CD207+ dendritic cells (DCs) drive emphysema by promoting CD8⁺ T cell cytotoxicity via Birbeck granule‐dependent MHC‐I antigen presentation. This DC subset is expanded by cigarette smoke‐induced oxidative stress, which triggers granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) release from airway epithelium.
Shurui Xuan, Yunhui Wu, Feng Liu, Heng Fu, Yaqi Meng, Yingwei Ou, Xijing Yuan, Ian M. Adcock, Man Jia, Xiaoning Zeng, Xin Yao   +10 more
wiley   +1 more source

Population‐Based Multi‐Omics and Cohort Study Identifying Predictive Biomarkers and Therapeutic Targets for Psoriatic Disease

Advanced Science, EarlyView.
Psoriatic disease (PsD) is a chronic skin disease, with challenges in early risk stratification and drug development. Through gene‐level causal inference framework and expression level validation, combined with longitudinal cohort study, CDSN and PRSS8 have been identified as candidate biomarkers and therapeutic targets for PsD.
Tianxing Wu, Jialiang Luo, Haoyuan Qiu, Weijie Shao, Yueyang Lu, Meixuan Luo, Zhaofeng Lin, Yan Zhang, Libo Zhang, Hong Wang, Jia Zhou, Guangfeng Ruan, Peihua Cao, Daming Zuo   +13 more
wiley   +1 more source